På taersklen til en ny epoke i behandling af kronisk hepatitis C-virusinfektion
Sammanfattning
Treatment of chronic hepatitis C virus (HCV) has for more than a decade been based upon use of pegylated interferon in
combination with ribavirin. Sustained virologic response rates are in general at a moderate level and severe adverse effects are
frequent. With the introduction of direct acting antivirals (DAA) we now face the possibility of interferon-free treatment with higher
response rates and less severe adverse effects. However, the costs of the DAAs are high presenting an additional economical burden
to the health sector calling for necessary priorities to be taken.